Home › Compare › NKOSF vs ABBV
NKOSF yields 4210.53% · ABBV yields 3.06%● Live data
📍 NKOSF pulled ahead of the other in Year 1
Combined, NKOSF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of NKOSF + ABBV for your $10,000?
Labrador Gold Corp. engages in the acquisition, exploration, and development of gold properties in the Americas. The company owns a 100% interest in the Borden Lake property that covers an area of 1,598-hectares located in Chapleau, Ontario. It has an option to acquire 100% interest in the Ashuanipi property consisting of 1,564 Claims in 10 claim blocks covering an area of approximately 391 square kilometers located in Labrador, Quebec; the Kingsway property consisting of 264 claims in 3 licenses covering approximately 77 square kilometers located near Gander, Newfoundland; and the Hopedale property that comprises 998 claims in 5 licenses covering 249 square kilometers. The company was formerly known as Nikos Explorations Ltd. and changed its name to Labrador Gold Corp. in December 2017. Labrador Gold Corp. was incorporated in 1987 and is headquartered in Toronto, Canada.
Full NKOSF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.